382 related articles for article (PubMed ID: 34724197)
1. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
Patel AB; Farooq S; Welborn M; Amaria RN; Chon SY; Diab A; Glitza Oliva IC; Huen AO; Li SQ; Nelson KC; Pacha O; Patel SP; Rapini RP; Tawbi HA; Wong MK; McQuade J; Davies MA; Haydu LE
Cancer; 2022 Mar; 128(5):975-983. PubMed ID: 34724197
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
3. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
4. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
5. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
7. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
8. Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER-Medicare database.
Almutairi AR; Slack M; Erstad BL; McBride A; Abraham I
Ther Adv Drug Saf; 2021; 12():2042098621991279. PubMed ID: 33796257
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
[No Abstract] [Full Text] [Related]
11. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous adverse effects of the immune checkpoint inhibitors.
Collins LK; Chapman MS; Carter JB; Samie FH
Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
[TBL] [Abstract][Full Text] [Related]
15. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
16. Dermatological side effects rarely interfere with the continuation of checkpoint inhibitor immunotherapy for cancer.
Rovers JFJ; Bovenschen HJ
Int J Dermatol; 2020 Dec; 59(12):1485-1490. PubMed ID: 32895923
[TBL] [Abstract][Full Text] [Related]
17. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
[TBL] [Abstract][Full Text] [Related]
18. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab use for the treatment of advanced melanoma.
Specenier P
Expert Opin Biol Ther; 2017 Jun; 17(6):765-780. PubMed ID: 28323504
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
Bhave P; Ahmed T; Lo SN; Shoushtari A; Zaremba A; Versluis JM; Mangana J; Weichenthal M; Si L; Lesimple T; Robert C; Trojanello C; Wicky A; Heywood R; Tran L; Batty K; Dimitriou F; Stansfeld A; Allayous C; Schwarze JK; Mooradian MJ; Klein O; Mehmi I; Roberts-Thomson R; Maurichi A; Yeoh HL; Khattak A; Zimmer L; Blank CU; Ramelyte E; Kähler KC; Roy S; Ascierto PA; Michielin O; Lorigan PC; Johnson DB; Plummer R; Lebbe C; Neyns B; Sullivan R; Hamid O; Santinami M; McArthur GA; Haydon AM; Long GV; Menzies AM; Carlino MS
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
